2014

JSS CRO in S-1226 Phase IIa

August 2, 2014 / by / News

JSS Research is a Contract Research Organization (CRO) based in Montreal with whom SolAeroMed is partnering to conduct our Phase IIa safety and effiacy trial on S-1226(8%). JSS Medical Research: Has over 25 years of experience in clinical research Has experience in more than 15 therapeutic areas Offers a full spectrum of services Is a

Read more

Australian S1226 patent granted

July 2, 2014 / by / News

SolAeroMed’s lead drug, S-1226, to treat asthma and other obstructive lung diseases now has issued patents in the EU, USA and most recenlty Australia.  Details at https://www.google.com/patents/WO2007071052A1?cl=en&dq=2006329199&hl=en&… SolAeroMed’s lead drug, S-1226, to treat asthma and other obstructive lung diseases is issued in throughout Europe.   In the USA the US patent office awarded nearly 2 addtional

Read more

SolAeroMed AGM 2014 minutes

June 12, 2014 / by / News

List of attendees: In person DC Birdsell Michael Flach Bryce Weaver Morenike Fadayomi Robert Commandeur Michael Smith Andrea Chiu John Butt Trish Smith Sharif Galal Pat Brown John Dennis Lorne Gould Megan McIntyre Evan Nelson Francis Green Gareth Lewis Cora Pieron Attending by phone Phyllis Kane Innovate Calgary Louis Bouchard   Apologies: Richard Leigh (held

Read more

S1226 Phase I Successfuly COMPLETED Q2 2014

May 20, 2014 / by / News

We are pleased to share that the S1226 Phase I Successfuly COMPLETED. We are currently analyzing the data and writing up the study results for submission to Health Canada. We are very pleased with the results which encourage us to believe there are no serious safey issues associated with our S1226 asthma drug. Prof Francis

Read more